Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-nitride-oxide (TiNO)-coated Optimax stent was superior to the Synergy everolimus-eluting stent (EES) in acute coronary syndrome (ACS) patients. Results were presented by Pasi Karjalainen, M.D., Heart Center, Satakunta Central Hospital, Pori, Finland.

Nuclear cardiology SPECT scan showing myocardial perfusion. A new consensus document issues by ACC and other societies provides guidelines on managing radiation dose.

May 31, 2018 — Here is a checklist of dose-sparing practices for nuclear cardiology that was included in a new 2018 consensus document to guide the optimal use of ionizing radiation in cardiovascular imaging.[1]
 

Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session at EuroPCR 2018, May 21-24 in Paris, France.

An example of an intra-aortic balloon pump (IABP) from Maquet. The results of the SEMPER FI trial. #europcr2018 #Europcr

May 31, 2018 — The results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study showed a positive trend in data presented at the EuroPCR 2018 Congress
An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now reaching epidemic levels worldwide with more than 1 billion patients considered to be suffering from hypertension today. Despite the availability of many safe and effective drugs, the control rates remain unacceptably low. This is mainly due to patient non-compliance in taking hypertension medications. 

Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology (ESC) Heart Failure 2018 World Congress, May 26-29 in Vienna, Austria. William T. Abraham, M.D., professor of medicine, physiology and cell biology and director, Division of Cardiovascular Medicine at the Ohio State University presented the data.

Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for calcified coronary artery disease (CAD). The company also announced the first patient enrollment in the DISRUPT CAD II post-market study by Prof. Jonathan Hill, M.D., at King’s College in London.

Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in its target patient population at one month following implantation of the Resolute Onyx drug-eluting stent (DES). The target population contained a high percentage of patients with complex coronary artery disease.

FFR-CT may soon replace invasive angiography for coronary lesion assessment. #EuroPCR 
FFR-CT may soon replace invasive angiography for coronary lesion assessment. #EuroPCR 

May 29, 2018 — Results from the innovative SYNTAX III Revolution Trial [1] underline the effectiveness of evolving noninvasive algorithms for fractional flow reserve assessed through computed tomography (FFR-CT) imaging. The data suggests heart teams should use this imaging-based technology for decision making. The data was presented as a late-breaking study at EuroPCR 2018.   

May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable coronary lesions to improve hard outcomes. Stable lesions include both patients with stable coronary artery disease as well as non-culprit lesions in hemodynamically stabilized acute coronary syndrome (ACS) patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now